JP2012211164A5 - - Google Patents

Download PDF

Info

Publication number
JP2012211164A5
JP2012211164A5 JP2012138485A JP2012138485A JP2012211164A5 JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5 JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012138485 A JP2012138485 A JP 2012138485A JP 2012211164 A5 JP2012211164 A5 JP 2012211164A5
Authority
JP
Japan
Prior art keywords
val xaa
xaa pro
xau
isomer
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012138485A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012211164A (ja
Filing date
Publication date
Priority claimed from US08/896,394 external-priority patent/US6143721A/en
Application filed filed Critical
Publication of JP2012211164A publication Critical patent/JP2012211164A/ja
Publication of JP2012211164A5 publication Critical patent/JP2012211164A5/ja
Pending legal-status Critical Current

Links

JP2012138485A 1997-07-18 2012-06-20 ドラスタチン15誘導体 Pending JP2012211164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives
US08/896,394 1997-07-18

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2008315263A Division JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Publications (2)

Publication Number Publication Date
JP2012211164A JP2012211164A (ja) 2012-11-01
JP2012211164A5 true JP2012211164A5 (enExample) 2013-01-10

Family

ID=25406130

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2012138485A Pending JP2012211164A (ja) 1997-07-18 2012-06-20 ドラスタチン15誘導体

Family Applications Before (3)

Application Number Title Priority Date Filing Date
JP2000503101A Expired - Fee Related JP4508413B2 (ja) 1997-07-18 1998-07-07 ドラスタチン15誘導体
JP2008315263A Expired - Fee Related JP5122429B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体
JP2008315269A Expired - Fee Related JP5047935B2 (ja) 1997-07-18 2008-12-11 ドラスタチン15誘導体

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200000132T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
AU2001227375A1 (en) 2000-02-08 2001-08-20 Herbert T. Nagasawa N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
AU2003228354B8 (en) * 2002-03-22 2010-03-04 Eisai R&D Management Co., Ltd. Hemiasterlin derivatives and uses thereof in the treatment of cancer
CA2802205C (en) * 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
US20060148014A1 (en) * 2004-12-09 2006-07-06 Sergei Agoulnik Tubulin isotype screening in cancer therapy using hemiasterlin analogs
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
MY159563A (en) 2006-05-16 2017-01-13 Pharmascience Inc Iap bir domain binding compounds
MY150531A (en) 2007-07-16 2014-01-30 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
RU2557319C2 (ru) 2007-07-16 2015-07-20 Дженентек, Инк. ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА ПРОТИВ CD79b И ИММУНОКОНЪЮГАТЫ И СПОСОБЫ ПРИМЕНЕНИЯ
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
DK2657253T3 (en) 2008-01-31 2017-10-09 Genentech Inc Anti-CD79b antibodies and immune conjugates and methods of use
CA2784748A1 (en) * 2009-12-18 2011-06-23 Idenix Pharmaceuticals, Inc. 5,5-fused arylene or heteroarylene hepatitis c virus inhibitors
US9173961B2 (en) 2010-02-10 2015-11-03 Immunogen, Inc. CD20 antibodies and uses thereof
NZ602368A (en) 2010-02-12 2014-10-31 Pharmascience Inc Iap bir domain binding compounds
EP2922818B1 (en) 2012-11-24 2018-09-05 Hangzhou Dac Biotech Co., Ltd Hydrophilic linkers and their uses for conjugation of drugs to cell binding molecules
AU2014384434B2 (en) 2014-02-28 2016-11-03 Hangzhou Dac Biotech Co., Ltd Charged linkers and their uses for conjugation
DK3262071T3 (da) 2014-09-23 2020-06-15 Hoffmann La Roche Fremgangsmåde til anvendelse af anti-CD79b-immunkonjugater
WO2015151078A2 (en) 2015-06-15 2015-10-08 Suzhou M-Conj Biotech Co., Ltd Hydrophilic linkers for conjugation
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR102345175B1 (ko) 2016-11-14 2021-12-31 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
WO2023033129A1 (ja) 2021-09-03 2023-03-09 東レ株式会社 癌の治療及び/又は予防用医薬組成物
CA3236930A1 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0598129B1 (en) * 1991-08-09 2000-03-22 Teikoku Hormone Mfg. Co., Ltd. Novel tetrapeptide derivative
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
WO1993017388A1 (en) 1992-02-26 1993-09-02 Clark Paul C System for protecting computers via intelligent tokens or smart cards
JP3523253B2 (ja) * 1992-05-20 2004-04-26 アボット ゲーエムベーハー ウント カンパニー カーゲー ドラスタチン誘導体
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
ATE196296T1 (de) * 1992-12-16 2000-09-15 Basf Ag Dolastatin analog
US5554993A (en) 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU728161B2 (en) 1997-01-10 2001-01-04 Silicon Gaming, Inc. Method and apparatus using geoographical position and a universal time to determination means to provide authenticated, secure, on-line communication between remote gaming locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Similar Documents

Publication Publication Date Title
JP2012211164A5 (enExample)
JP2011511805A5 (enExample)
JP2016538254A5 (enExample)
JP2007269812A5 (enExample)
JP2010534684A5 (enExample)
SG10201909122QA (en) Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases
ES2603058T3 (es) Láminas, esponjas y bayetas revestidas de un tratamiento antimicrobiano
JP2013518057A5 (enExample)
JP2013542247A5 (enExample)
JP2009225798A5 (enExample)
JP2012530060A5 (enExample)
JP2012502037A5 (enExample)
JP2015024998A5 (enExample)
JP2015518055A5 (enExample)
JP2014515013A5 (enExample)
JP2009535462A5 (enExample)
JP2011168603A5 (enExample)
JP2008513467A5 (enExample)
JP2007527914A5 (enExample)
JP2013520405A5 (enExample)
EP2588099A4 (en) METHOD OF TREATING THE RESTLESS LEG SYNDROME
JP2011137005A5 (enExample)
CL2008003322A1 (es) Compuestos derivados de acidos de ciclobutanoamino, moduladores de receptores s1p; composicion farmaceutica; procedimiento de preparacion; y uso en el tratamiento de artritis, enfermedades autoinmunes, diabetes tipo i, enfermedad pulmonar obstructiva cronica, entre otras.
JP2013503110A5 (enExample)
CL2007000680A1 (es) Compuesto cristalino (5s)-5-[4(cloro-piridin-2-iloxi)-piperidin-1-sulfonilmetil]-5-metil-imidazolidin-2,4-diona, forma g; proceso de preparacion; composicion farmaceutica; y uso para el tratamiento de epoc.